Stockreport

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics  Today, Compa [Read more]